company background image
APLS logo

Apellis Pharmaceuticals NasdaqGS:APLS Stock Report

Last Price

US$27.75

Market Cap

US$3.4b

7D

-1.1%

1Y

-41.7%

Updated

21 Nov, 2024

Data

Company Financials +

Apellis Pharmaceuticals, Inc.

NasdaqGS:APLS Stock Report

Market Cap: US$3.4b

APLS Stock Overview

A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. More details

APLS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Apellis Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Apellis Pharmaceuticals
Historical stock prices
Current Share PriceUS$27.75
52 Week HighUS$73.80
52 Week LowUS$24.34
Beta0.87
11 Month Change0.54%
3 Month Change-30.82%
1 Year Change-41.74%
33 Year Change-38.35%
5 Year Change0.76%
Change since IPO97.79%

Recent News & Updates

Recent updates

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Oct 18
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Oct 01

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Sep 27
Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 09

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12
Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30
What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30
It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19
With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13
Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Shareholder Returns

APLSUS BiotechsUS Market
7D-1.1%-6.5%-1.0%
1Y-41.7%14.6%30.3%

Return vs Industry: APLS underperformed the US Biotechs industry which returned 14.6% over the past year.

Return vs Market: APLS underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is APLS's price volatile compared to industry and market?
APLS volatility
APLS Average Weekly Movement7.0%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: APLS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: APLS's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009704Cedric Francoiswww.apellis.com

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.

Apellis Pharmaceuticals, Inc. Fundamentals Summary

How do Apellis Pharmaceuticals's earnings and revenue compare to its market cap?
APLS fundamental statistics
Market capUS$3.42b
Earnings (TTM)-US$250.10m
Revenue (TTM)US$715.22m

4.8x

P/S Ratio

-13.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APLS income statement (TTM)
RevenueUS$715.22m
Cost of RevenueUS$417.28m
Gross ProfitUS$297.94m
Other ExpensesUS$548.04m
Earnings-US$250.10m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.01
Gross Margin41.66%
Net Profit Margin-34.97%
Debt/Equity Ratio190.7%

How did APLS perform over the long term?

See historical performance and comparison